Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?

Luxiang Wang^{1

2}, Chunli Zhang³, Shuang Fan^{4

5

6}, Xiaodong Mo^{4

5

6}, Xiaoxia Hu^{1

2}

Affiliations

¹ Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China.
² Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁴ Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
⁵ Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
⁶ Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China.

Review

Luxiang Wang et al. Innovation (Camb). 2023.

. 2023 Jun 20;4(4):100461.

doi: 10.1016/j.xinn.2023.100461. eCollection 2023 Jul 10.

Luxiang Wang^{1

2}, Chunli Zhang³, Shuang Fan^{4

5

6}, Xiaodong Mo^{4

5

6}, Xiaoxia Hu^{1

2}

¹ Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China.
² Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁴ Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
⁵ Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
⁶ Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Bornhäuser M., Schliemann C., Schetelig J., et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2023;9:519–526. - PMC - PubMed
1. Dillon L.W., Gui G., Page K.M., et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745–755. - PMC - PubMed
1. Venditti A., Piciocchi A., Candoni A., et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134:935–945. - PubMed
1. Jentzsch M., Bischof L., Backhaus D., et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022;6:4570–4580. - PMC - PubMed
1. Lv M., Wang Y., Chang Y.J., et al. Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission. Clin. Cancer Res. 2019;25:1737–1748. - PubMed